The U.S. Food and Drug Administration approved Heron Therapeutics Inc.’s supplemental New Drug Application for Cinvanti (aprepitant) injectable emulsion for intravenous use.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00PR Newswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngPR Newswire2019-10-22 08:30:162019-10-22 12:58:43FDA Approves Supplemental New Drug Application to Expand Heron’s Cinvanti Label
